Recent advances in the biological understanding of thyroid cancer have led to the development of targeted therapies, such as the tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib, which have been approved by the US Food and Drug Administration for the treatment of differentiated thyroid cancer. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD, PhD, from National Cancer Center Hospital East, Kashiwa, Japan, evaluates the efficacy and safety of early versus delayed use of TKIs for the management of patients with thyroid cancer.
Early versus delayed use of tyrosine kinase inhibitors for thyroid cancer
14th June 2016
Oncology
